NeuroOne Medical Technologies gains FDA 510(k) clearance for Evo SEEG electrode

300

neuroone evo technologyNeuroOne Medical Technologies—a company focused on improving surgical care options and outcomes for patients with neurological disorders—has announced that it has received US Food and Drug Administration (FDA) 510(k) clearance to market its Evo stereoelectroencephalography (SEEG) electrode technology for temporary (less than 24 hours) use with recording, monitoring and stimulation equipment for the recording, monitoring, and stimulation, of electrical signals at the subsurface level of the brain.

The Evo SEEG electrode represents the company’s second FDA 510(k)-cleared product, providing a full line of electrode technologies to address an estimated worldwide market of US$100 million for patients requiring diagnostic brain mapping procedures, according to a press release. As opposed to cortical electrodes, SEEG electrodes provide a similar function at the subsurface level of the brain by using a much less invasive process that does not require removal of the top portion of the patient’s skull. It has become the predominant technology used in these procedures due to its less invasive placement and subsurface location, the release adds.

NeuroOne’s Evo cortical and SEEG electrodes are a portfolio of high-definition, thin film electrodes. Potential associated advantages include increased signal clarity and reduced noise; better tactile feedback during insertion into brain tissue; and faster order fulfilment due to an automated manufacturing process.

NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use in deep brain stimulation (DBS) and spinal cord stimulation (SCS) for chronic back pain.  These therapeutic electrode technologies represent addressable markets between US$500 million and US$6 billion.

“This represents yet another critical milestone met by the company as we continue to execute our strategy,” said Dave Rosa, CEO of NeuroOne. “The next steps for the company are to expand the SEEG labelling for longer term use, which we believe will be a key part of our commercialisation strategy for the Evo SEEG electrode, and complete development of an SEEG ablation electrode/probe for ablation of brain tissue and permanently implanted stimulation electrodes for patients with chronic applications, such as epilepsy, Parkinson’s disease and chronic back pain.”

The press release concludes that NeuroOne expects to be launch-ready by the end of the calendar year 2021—pending additional regulatory clearance of SEEG labelling for longer term use.


LEAVE A REPLY

Please enter your comment!
Please enter your name here